Papers: 10.1371/journal.pone.0200996

https://doi.org/10.1371/journal.pone.0200996

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

Cited by: 9
Author(s): Damien Côté, Alex J. Eustace, Sinéad Toomey, Mattia Cremona, Małgorzata Milewska, Simon J. Furney, Aoife Carr, Joanna Fay, Elaine W. Kay, Susan Kennedy, John Crown, Bryan T. Hennessy, Stephen F. Madden
Published: about 8 years ago

Software Mentions 1